Changing possibilities in haemophilia through patient focus
Novo Nordisk is focused on the quality of life of people living with haemophilia; for this reason our pipeline continues to evolve, it is why we continue to strengthen our existing formula.
At Novo Nordisk we have over 4,000 people working in research and development, many of them in haemophilia. Their long-term objective is clear: improving the lives of people with haemophilia. We are continuing our efforts in R&D for people with haemophilia and inhibitors. But our experience in the field has demonstrated that we have more to offer, and so the future will see us expanding our portfolio and developing new treatments, not only for people with haemophilia and inhibitors, but for the haemophilia community in general. At Novo Nordisk we continue to redefine treatment and develop safe, effective and more convenient approaches: we continue to change possibilities in haemophilia.
